Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 7 21:00

CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15

Futu NewsJan 3 05:31 · Ratings

Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating

Futu NewsJan 2 23:32 · Ratings

Analysts Offer Insights on Healthcare Companies: Bioventus (BVS), Corvus Pharmaceuticals (CRVS) and Lifecore Biomedical (LFCR)

TipRanksJan 2 23:00 · Ratings

Press Release: Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners

Dow JonesJan 2 21:00

Express News | Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners

BreakingsJan 2 21:00